Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Published:2020-01 Issue:1 Volume:8 Page:25-33
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Richeldi Luca,Fernández Pérez Evans R,Costabel Ulrich,Albera Carlo,Lederer David J,Flaherty Kevin R,Ettinger Neil,Perez Rafael,Scholand Mary Beth,Goldin Jonathan,Peony Yu Kin-Hung,Neff Thomas,Porter Seth,Zhong Ming,Gorina Eduard,Kouchakji Elias,Raghu Ganesh

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference24 articles.

1. Idiopathic pulmonary fibrosis;Martinez;Nat Rev Dis Primers,2017

2. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

3. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11;Raghu;Lancet Respir Med,2014

4. Idiopathic pulmonary fibrosis;Richeldi;Lancet,2017

5. An Official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline;Raghu;Am J Respir Crit Care Med,2015

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis;Pharmaceutical Science Advances;2024-12

2. A Review of Pathophysiology and Therapeutic Strategies Targeting TGF-β in Graves’ Ophthalmopathy;Cells;2024-09-05

3. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF);Expert Review of Clinical Pharmacology;2024-08-27

4. When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis;JAMA;2024-08-06

5. Pamrevlumab for Idiopathic Pulmonary Fibrosis;JAMA;2024-08-06